Role of interferon in melanoma: old hopes and new perspectives

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity

(2016) Alexander M.M. Eggermont et al.   EUROPEAN JOURNAL OF CANCER

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma

(2016) Yong Xin et al.   MEDICINE

Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma

(2016) Ruth Heise et al.   PLoS One

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives

(2015) Martina Sanlorenzo et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Immune Checkpoint Blockade and Interferon-α in Melanoma

(2015) Imran Rafique et al.   SEMINARS IN ONCOLOGY

Dynamic control of type I IFN signalling by an integrated network of negative regulators

(2015) Rebecca A. Porritt et al.   TRENDS IN IMMUNOLOGY

Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma

(2014) L. Ferrari de Andrade et al.   CANCER RESEARCH

Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis

(2014) Mei Qin et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Trial Watch

(2014) Fernando Aranda et al.   OncoImmunology

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence

(2013) Miranda J. Payne et al.   JOURNAL OF CLINICAL ONCOLOGY

Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy

(2013) Serge Y. Fuchs   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Pediatric Phase II Trials of Poly-ICLC in the Management of Newly Diagnosed and Recurrent Brain Tumors

(2013) Lisa L.R. Hartman et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

(2013) Paolo A Ascierto et al.   Journal of Translational Medicine

Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice

(2013) Mi Ryung Roh et al.   MELANOMA RESEARCH

Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells

(2013) Bishu Sapkota et al.   OncoImmunology

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

(2013) Zachary A Cooper et al.   OncoImmunology

Adjuvant therapy with pegylated interferon alfa-2b (36months) versus low-dose interferon alfa-2b (18months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study

(2012) Jean Jacques Grob et al.   EUROPEAN JOURNAL OF CANCER

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

(2012) Alexander M.M. Eggermont et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses

(2012) S Bhattacharya et al.   ONCOGENE

Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis

(2011) H. Zheng et al.   BLOOD

Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991

(2011) Alexander M.M. Eggermont et al.   EUROPEAN JOURNAL OF CANCER

Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma

(2011) Ahmad A. Tarhini et al.   JOURNAL OF CLINICAL ONCOLOGY

Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients

(2011) Diana L Simons et al.   Journal of Translational Medicine

Inflammatory signaling compromises cell responses to interferon alpha

(2011) W-C HuangFu et al.   ONCOGENE

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

(2010) G. Schiavoni et al.   CANCER RESEARCH

Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma

(2010) Maja A. Hofmann et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis

(2010) S. Mocellin et al.   JNCI-Journal of the National Cancer Institute

Ligand-Stimulated Downregulation of the Alpha Interferon Receptor: Role of Protein Kinase D2

(2010) H. Zheng et al.   MOLECULAR AND CELLULAR BIOLOGY

Clinical and Immunologic Basis of Interferon Therapy in Melanoma

(2009) Ahmad A. Tarhini et al.   Annals of the New York Academy of Sciences

Clinical Use of Interferon-γ

(2009) Catriona H.T. Miller et al.   Annals of the New York Academy of Sciences

Adjuvant low-dose interferon  2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis

(2008) C. Garbe et al.   ANNALS OF ONCOLOGY

Interferon-β therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells

(2008) Hitomi Kubo et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Mutation of the IFNAR-1 Receptor Binding Site of Human IFN-α2 Generates Type I IFN Competitive Antagonists†

(2008) Manjing Pan et al.   BIOCHEMISTRY

Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade

(2008) A. Ribas et al.   CLINICAL CANCER RESEARCH

VEGF Secretion is Inhibited by Interferon-Alpha in Several Melanoma Cell Lines

(2008) Ene T. Raig et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

(2008) Alexander MM Eggermont et al.   LANCET